Literature DB >> 9629442

Evaluation of seminal plasma parameters in patients with chronic prostatitis or leukocytospermia.

M Ludwig1, C Kümmel, I Schroeder-Printzen, R H Ringert, W Weidner.   

Abstract

Though detailed cytological and microbiological diagnostic procedures are routinely carried out in male genital tract infection, the correct diagnosis and localization of inflammation or infection is often difficult. In this prospective study, the relevance of the seminal plasma markers PMN elastase, complement C3, CRP, fructose, PSP 94, PSA, and alpha-glucosidase was investigated in 13 patients with chronic prostatitis, 31 patients with significant leukocytospermia, and 58 patients with non-inflammatory diseases (controls). Statistically relevant results were obtained for PMN elastase when comparing chronic prostatitis with controls, leukocytospermia with controls (P < 0.001) and chronic prostatitis with leukocytospermia (P < 0.05); for complement C3 chronic prostatitis and leukocytospermia vs. controls (P < 0.05) and for fructose/ejaculate leukocytospermia vs. controls (P < 0.05). No statistically relevant differences were found for C-reactive protein, alpha-glucosidase, PSA and prostatic secretory protein (PSP 94). To delimit genital tract inflammation from non-inflammatory patients, cutpoint levels for PMN elastase of 230 ng ml-1 and for C3c of 0.01 g l-1 were suggested. PMN elastase was shown to possess the strongest discriminating power. The assessment of a cutpoint for fructose to indicate seminal vesicle dysfunction is not possible as the significance level is weak (P < 0.05).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9629442     DOI: 10.1111/j.1439-0272.1998.tb02825.x

Source DB:  PubMed          Journal:  Andrologia        ISSN: 0303-4569            Impact factor:   2.775


  13 in total

1.  Characterization of the seminal plasma proteome in men with prostatitis by mass spectrometry.

Authors:  Daniel Kagedan; Irene Lecker; Ihor Batruch; Christopher Smith; Ilia Kaploun; Kirk Lo; Ethan Grober; Eleftherios P Diamandis; Keith A Jarvi
Journal:  Clin Proteomics       Date:  2012-02-06       Impact factor: 3.988

2.  Autoimmune T cell responses to seminal plasma in chronic pelvic pain syndrome (CPPS).

Authors:  G R D Batstone; A Doble; J S H Gaston
Journal:  Clin Exp Immunol       Date:  2002-05       Impact factor: 4.330

Review 3.  [Male adnexitis].

Authors:  T Diemer; O Gralla
Journal:  Urologe A       Date:  2008-12       Impact factor: 0.639

Review 4.  [Chronic pain syndrome in uorology].

Authors:  S Krege; M Ludwig; M Kloke; H Rübben
Journal:  Urologe A       Date:  2003-04-11       Impact factor: 0.639

5.  Chronic prostatitis/chronic pelvic pain pyndrome): seminal markers of inflammation.

Authors:  Martin Ludwig; Andreas Vidal; Thorsten Diemer; Wolfgang Pabst; Klaus Failing; Wolfgang Weidner
Journal:  World J Urol       Date:  2003-04-11       Impact factor: 4.226

Review 6.  Prostatitis versus pelvic pain syndrome: immunologic studies.

Authors:  Caroline Maake; Hubert John
Journal:  Curr Urol Rep       Date:  2003-08       Impact factor: 2.862

7.  Procalcitonin as a useful marker to decide upon intervention for urinary tract infection.

Authors:  Koichi Sugimoto; Nobutaka Shimizu; Naoki Matsumura; Takashi Oki; Kazuhiro Nose; Tsukasa Nishioka; Hirotsugu Uemura
Journal:  Infect Drug Resist       Date:  2013-08-07       Impact factor: 4.003

Review 8.  Prostatitis and male infertility: evidence and links.

Authors:  Richard A Schoor
Journal:  Curr Urol Rep       Date:  2002-08       Impact factor: 2.862

9.  The NIH Consensus concept of chronic prostatitis/chronic pelvic pain syndrome compared with traditional concepts of nonbacterial prostatitis and prostatodynia.

Authors:  John N Krieger; Susan O Ross; Leslie Deutsch; Donald E Riley
Journal:  Curr Urol Rep       Date:  2002-08       Impact factor: 2.862

10.  A Pilot Comparative Study of 26 Biochemical Markers in Seminal Plasma and Serum in Infertile Men.

Authors:  Rui-Xiang Feng; Jin-Chun Lu; Hong-Ye Zhang; Nian-Qing Lü
Journal:  Biomed Res Int       Date:  2015-10-11       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.